როგორ უნდა ციტირება
ანოტაცია
Allergic rhinitis is a common condition, affecting between10% and 40% of people worldwide. The ARIA (Allergic Rhin-itis and its Impact on Asthma) guidelines [5] recommendallergen avoidance as first-line treatment, followed by phar-macotherapy. Specific immunotherapy is recommended forpatients with more severe diseases who do not respond tostandard therapy. Although the effectiveness of SCIT (Sub-cutaneous Immunotherapy) has been proven, it is inconve-nient and time-consuming. In addition, it sometimes causeslocal and systemic side effects, which is why its alternativemethod, SLIT (Sublingual immunotherapy), has been pro-posed in recent years. Research in the field of sublingualimmunotherapy has continued since 2002. According to sev-eral original Cochrane Review, questions remained about thesafety and efficacy of sublingual immunotherapy for peoplewith rhinitis [2].Since polysensitisation to various allergens is quite com-mon in allergic rhinitis, choosing vaccines for specific immu-notherapy is usually challenging [3]. It is also interesting tosee how effective immunotherapy with dominant allergenscan be in such polysensitised patients and whether it is es-sential to consider different demographic data when select-ing a vaccine [4].The study aimed to compare immunotherapy’s efficacy,safety, cost and standard care in patients with allergic rhinitis